A drug stent is filled with medication for time-disposal. It is pushed into the blood stream slowly to prevent it from being damaged again. According to research published in American Family Physician, about 40% of patients with angioplasticity or stent experience have restenosis. This means that the surgery of an artery is developing again. When done with a bare stent, this percentage decreases to about 30%. If a drug stent is used, it drops to less than 10%.

Market Insights

The drug eluting stent demand is largely motivated by a rise in the global geriatric population as they are extremely vulnerable to arterial disorders. Furthermore, the growing prevalence and occurrence of chronic atherosclerosis and obesity is likely to lead to the development of the medication eluting stent markets of the next century. For instance, according to the research conducted, more than 15.8 million people suffer from coronary artery disease, and nearly 8 million suffer from heart attacks. However, factors such as reduction in the drug-eluting stents pricing, and availability of alternative therapy procedure are the major obstacle to the growth of drug eluting stent market. Increasing preference for drugs over the surgical procedure of stent implants and increased risk of developing late-stage thrombosis are limiting the growth of drug-eluting stent market.

The increasing prevalence of chronic diseases like diabetes or heart attack is expected to fuel demand in the near future for drug eluting stents. The related advantages include a reduced risk of clotting the blood without affecting the endothelium. Consequently, they would be ideal for diabetic patients when introducing such products.

Report coverage

The market research study on “Drug Eluting Stent Market (By Drug: Sirolimus, Paclitaxel, Zotaroliums, Everoliums, Bioliums, Others; By Coating Type: Polymer Based Coating, Polymer Free Coatings; By Application: Coronary Artery Diseases, Peripheral Artery Diseases; By End-User: Cardiology Centers, Ambulatory Surgery Centers (ASCs), Hospitals) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2020 - 2027” offers detailed insights on the global drug eluting stent market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report also provides competitive landscape to understand the current stance of particular player. The report provides insights on global drug eluting stent market are drug, coating type, application, end-user and major geographic regions. The drug eluting stent market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. For each region, the market size for different segments has been covered under the scope of report.

North America accounts to hold large market share of global drug eluting stent market. The region is attributed to the stringent government regulations for manufacturing medical equipment and approval. Furthermore, the availability of reimbursement combined with a high rate of occurrence of heart disease is expected to improve the growth of North American market. In the projected period, the fastest development will occur in China, India, Brazil, and South Africa. In additional, patient awareness about the commercial supply of drugs, government financing, the continuous development of healthcare services and rising healthcare spending are the factors that lead to a substantial market growth in these country. Asia Pacific and Latin America is expected show a significant growth rate during forecast period 2020 - 2027. However, there has been steady growth throughout the projected period in the Middle East & Africa market.

Key Players

Key aspects such as the company's overview, product portfolio, financial perspective, current developments and competitive business strategies are the key players operating in the global drug elutting stent market. Major players operating in the market are Cook Medical, Abbott Laboratories, Cordis Corporation, Boston Scientific Corporation, Xtent, Inc., Medtronic plc, Johnson and Johnson, Stentys, MicroPort Scientific Corporation, Biotronik Inc., Biosensors International Group, and others.

The global drug eluting stent market is segmented as below:

Market Segmentation

Drug Eluting Stent Market By Drug

• Sirolimus
• Paclitaxel
• Zotaroliums
• Everoliums
• Bioliums
• Others

Drug Eluting Stent Market By Coating Type

• Polymer Based Coating
• Polymer Free Coatings

Drug Eluting Stent Market By Application

• Coronary Artery Diseases
• Peripheral Artery Diseases

Drug Eluting Stent Market By End-User

• Cardiology Centers
• Ambulatory Surgery Centers (ASCs)
• Hospitals

Drug Eluting Stent Market By Geography

North America

• U.S
• Canada

Europe

• UK
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa